Doherty T

Johnson & Johnson, Horsham, PA.

6 papers

ArticleKetamine

Comment on Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions.

Ahmed M, Cabrera P, Doherty T +4

Europe PMC2026
ArticleKetamine

Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study.

Zaki N, Chen LN, Lane R +7

Europe PMC2026
ArticleKetamine

Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.

Canuso CM, Bossie C, Fu DJ +12

Europe PMC2025
ArticleKetamine

Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval.

Sanacora G, Ahmed M, Brown B +11

Europe PMC2025
ArticleKetamine

Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study.

Zaki N, Chen LN, Lane R +10

Europe PMC2025
ArticleKetamine

Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression.

Chepke C, Shelton R, Sanacora G +3

Europe PMC2024